Citations

Showing 10 of 108094 citations.

Decreased Gut Microbiome Tryptophan Metabolism and Serotonergic Signaling in Patients With Persistent Mental Health and Gastrointestinal Symptoms After COVID-19
Blackett, John W. , Sun, Yiwei , Elkind, Mitchell S.V. , O’Byrne, Sheila M., Freedberg, Daniel E. , Purpura, Lawrence J. , Margolis, Kara Gross , Wainberg, Milton L. , Abrams, Julian A , Wang, Harris H. , Chang, Lin

Mayo Clinic

Clinical and Translational Gastroenterology | September 1, 2022 | Volume: 13 | Issue: 10 | Pages: e00524

10.14309/ctg.0000000000000524 | PMID 36049050 Get It

INTRODUCTION: An estimated 15%–29% of patients report new gastrointestinal (GI) symptoms after coronavirus-19 disease (COVID-19) while 4%–31% report new depressive symptoms. These symptoms may be secondary to gut microbiome tryptophan metabolism and 5-hydroxytryptamine (5-HT)-based signaling. METHODS: This study used specimens from 2 patient cohorts: (i) fecal samples from patients with acute COVID-19 who participated in a randomized controlled trial testing prebiotic fiber and (ii) blood samples from patients with acute COVID-19. Six months after recovering from COVID-19, both cohorts answered questions related to GI symptoms and anxiety or depression. Microbiome composition and function, focusing on tryptophan metabolism-associated pathways, and plasma 5-HT were assessed. RESULTS: In the first cohort (n = 13), gut microbiome L-tryptophan biosynthesis during acute COVID-19 was decreased among those who developed more severe GI symptoms (2.0-fold lower log activity comparing those with the most severe GI symptoms vs those with no symptoms, P = 0.06). All tryptophan pathways showed decreased activity among those with more GI symptoms. The same pathways were also decreased in those with the most severe mental health symptoms after COVID-19. In an untargeted analysis, 5 additional metabolic pathways significantly differed based on subsequent development of GI symptoms. In the second cohort (n = 39), plasma 5-HT concentration at the time of COVID-19 was increased 5.1-fold in those with GI symptoms alone compared with those with mental health symptoms alone ( P = 0.02). DISCUSSION: Acute gut microbiome-mediated reduction in 5-HT signaling may contribute to long-term GI and mental health symptoms after COVID-19. Future studies should explore modification of 5-HT signaling to reduce post-COVID symptoms.
AACC Guidance Document on the Use of Point-of-Care Testing in Fertility and Reproduction
Nichols, James H. , Ali, Mahesheema , Anetor, John I. , Chen, Li Sheng, Chen, Yu , Das, Saswati , Karon, Brad S. , Kary, Heba, Nerenz, Robert D , Rai, Alex J, Shajani-Yi, Zahra, Thakur, Vinita , Wang, Sihe , Yu, Hoi Ying Elsie, Zamora, Lindsey E , Das, Saswati , Nichols, James H , Collins, Sean P. , Devaraj, Sridevi , Fu, Lei , Rai, Alex J

Mayo Clinic

The Journal of Applied Laboratory Medicine | September 1, 2022 | Volume: 7 | Issue: 5 | Pages: 1202-1236

10.1093/jalm/jfac042 | PMID 36047824 Get It

Abstract Background The AACC Academy revised the reproductive testing section of the Laboratory Medicine Practice Guidelines: Evidence-Based Practice for Point-of-Care Testing (POCT) published in 2007. Methods A panel of Academy members with expertise in POCT and laboratory medicine was formed to develop guidance for the use of POCT in reproductive health, specifically ovulation, pregnancy, premature rupture of membranes (PROM), and high-risk deliveries. The committee was supplemented with clinicians having Emergency Medicine and Obstetrics/Gynecology training. Results Key recommendations include the following. First, urine luteinizing hormone (LH) tests are accurate and reliable predictors of ovulation. Studies have shown that the use of ovulation predicting kits may improve the likelihood of conception among healthy fertile women seeking pregnancy. Urinary LH point-of-care testing demonstrates a comparable performance among other ovulation monitoring methods for timing intrauterine insemination and confirming sufficient ovulation induction before oocyte retrieval during in vitro fertilization. Second, pregnancy POCT should be considered in clinical situations where rapid diagnosis of pregnancy is needed for treatment decisions, and laboratory analysis cannot meet the required turnaround time. Third, PROM testing using commercial kits alone is not recommended without clinical signs of rupture of membranes, such as leakage of amniotic fluid from the cervical opening. Finally, fetal scalp lactate is used more than fetal scalp pH for fetal acidosis due to higher success rate and low volume of sample required. Conclusions This revision of the AACC Academy POCT guidelines provides recommendations for best practice use of POCT in fertility and reproduction.
Benefits of Meniscal Repair in Selected Patients Aged 60 Years and Older
Husen, Martin , Kennedy, Nicholas I. , Till, Sara E., Reinholz, Anna K., Krych, Aaron J. , Saris, Daniël B.F. , Till, Sara, Reinholz, Anna, Krych, Aaron J , Stuart, Michael J.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | September 1, 2022 | Volume: 10 | Issue: 9 | Pages: No page available

10.1177/23259671221117491 | PMID 36081411 Get It

Background: Little is known about the benefits and outcomes of meniscal repair in patients older than 60 years. Purpose: To (1) report the clinical and radiographic outcomes of meniscal repair in patients aged ≥60 years and compare them with matched patients who underwent meniscectomy and (2) identify procedural failures. Study Design: Cohort study; Level of evidence, 2. Methods: We included 32 knees in 32 patients aged ≥60 years (20 female, 12 male; mean age, 64.5 ± 4.6 years) who underwent meniscal repair surgery at a single medical institution between 2010 and 2020. Patients were matched according to age, sex, body mass index, and meniscal tear type with a comparison cohort who underwent meniscectomy (n = 49 patients [49 knees]; 32 female, 17 male). For all patients, demographic information, clinical history, physical examination findings, treatment details, and radiographic images were reviewed and analyzed. At final follow-up (mean, 42.2 months; range, 13-128 months), patients completed the 2000 International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Form, Knee injury and Osteoarthritis Outcome Score (KOOS), and Lysholm score. Clinical failure was defined as revision surgery and/or progression to total knee arthroplasty (TKA). A matched-pairs t test was used to analyze differences between the 2 treatment groups, and Kaplan-Meier analysis was used to determine the rates of knee osteoarthritis and progression to TKA. Results: The majority of patients had a medial meniscal tear (72.8%), whereas the lateral meniscus was torn in 27.2% of cases. Most tears were located in the meniscal root (56.8%), followed by the posterior horn (34.6%) and midbody (8.6%). At final follow-up, all outcome scores were higher in the repair group compared with the meniscectomy group (IKDC, 78.9 ± 13.4 vs 56.0 ± 15.4; KOOS, 86.6 ± 11.9 vs 61.7 ± 16.2; Lysholm, 88.3 ± 13.3 vs 68.7 ± 15.2, respectively; P < .001 for all). Clinical failure was observed in 22% of patients in the repair group. Conclusion: All clinical outcome scores were higher in the meniscal repair group compared with the matched meniscectomy group at final follow-up. The clinical failure rate of the repair group was 22%. These findings support meniscal repair in selected patients aged ≥60 years.
The Goals and Outcomes of Adolescent and Young Adults with POTS Attending an Intensive Interdisciplinary Treatment Program
Oetjen, Laurel , Johannsen, Amanda, Bean, Jessica R., Sim, Leslie , Harrison, Tracy E. , Owens, Michele Tsai , Harbeck‐Weber, Cynthia , Bean, Jessica, Harrison, Tracy, Johannsen, Amanda L, Bean, Jessica, Harbeck‐Weber, Cynthia

Mayo Clinic

Occupational Therapy In Health Care | September 1, 2022 | Volume: 38 | Issue: 3 | Pages: 768-782

10.1080/07380577.2022.2116666 | PMID 36047810 Get It

Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
Deng, Jing , Paulus, Aneel , Fang, Douglas D. , Manna, Alak , Wang, Guangfeng , Wang, Hengbang , Zhu, Saijie , Chen, Jianyong , Min, Ping , Yin, Yan , Dutta, Navnita , Halder, Nabanita , Ciccio, Gina , Copland, John A. , Miller, James L. , Han, Bing , Bai, Longchuan , Liu, Liu , Wang, Mi , McEachern, Donna , Przybranowski, Sally , Yang, Chao‐Yie , Stuckey, Jeanne A. , Li, Caixia , Letai, Anthony , Yang, Dajun , Wang, Shaomeng , Chanan‐Khan, Asher , Miller, James , Wu, Depei , Li, Caixia , Ryan, Jeremy , Letai, Anthony , Ailawadhi, Sikander , Yang, Dajun , Wang, Shaomeng , Chanan-Khan, Asher , Zhai, Yifan , Paulus, Aneel , Ryan, Jeremy , Ailawadhi, Sikander

Mayo Clinic

Clinical Cancer Research | September 1, 2022 | Volume: 28 | Issue: 24 | Pages: 5455-5468

10.1158/1078-0432.ccr-21-4037 | PMID 36048524 Get It

Abstract Purpose: Development of B-cell lymphoma 2 (BCL-2)–specific inhibitors poses unique challenges in drug design because of BCL-2 homology domain 3 (BH3) shared homology between BCL-2 family members and the shallow surface of their protein–protein interactions. We report herein discovery and extensive preclinical investigation of lisaftoclax (APG-2575). Experimental Design: Computational modeling was used to design “lead” compounds. Biochemical binding, mitochondrial BH3 profiling, and cell-based viability or apoptosis assays were used to determine the selectivity and potency of BCL-2 inhibitor lisaftoclax. The antitumor effects of lisaftoclax were also evaluated in several xenograft models. Results: Lisaftoclax selectively binds BCL-2 (Ki &lt; 0.1 nmol/L), disrupts BCL-2:BIM complexes, and compromises mitochondrial outer membrane potential, culminating in BAX/BAK-dependent, caspase-mediated apoptosis. Lisaftoclax exerted strong antitumor activity in hematologic cancer cell lines and tumor cells from patients with chronic lymphocytic leukemia, multiple myeloma, or Waldenström macroglobulinemia. After lisaftoclax treatment, prodeath proteins BCL-2‒like protein 11 (BIM) and Noxa increased, and BIM translocated from cytosol to mitochondria. Consistent with these apoptotic activities, lisaftoclax entered malignant cells rapidly, reached plateau in 2 hours, and significantly downregulated mitochondrial respiratory function and ATP production. Furthermore, lisaftoclax inhibited tumor growth in xenograft models, correlating with caspase activation, poly (ADP-ribose) polymerase 1 cleavage, and pharmacokinetics of the compound. Lisaftoclax combined with rituximab or bendamustine/rituximab enhanced antitumor activity in vivo. Conclusions: These findings demonstrate that lisaftoclax is a novel, orally bioavailable BH3 mimetic BCL-2–selective inhibitor with considerable potential for the treatment of certain hematologic malignancies.
TRIT1 defect leads to a recognizable phenotype of myoclonic epilepsy, speech delay, strabismus, progressive spasticity, and normal lactate levels
Muylle, Ewout , Jiang, Huafang , Johnsen, Christin , Byeon, Seul Kee , Ranatunga, Wasantha , Garapati, Kishore , Zenka, Roman M. , Preston, Graeme , Pandey, Akhilesh , Fang, Fang , Morava, Eva , Pandey, Akhilesh , Byeon, Seul Kee , Garapati, Kishore , Kozicz, Tamás , Morava, Éva

Mayo Clinic

Journal of Inherited Metabolic Disease | September 1, 2022 | Volume: 45 | Issue: 6 | Pages: 1039-1047

10.1002/jimd.12550 | PMID 36047296 Get It

AbstractTRIT1 defect is a rare, autosomal‐recessive disorder of transcription, initially described as a condition with developmental delay, myoclonic seizures, and abnormal mitochondrial function. Currently, only 13 patients have been reported. We reviewed the genetic, clinical, and metabolic aspects of the disease in all known patients, including two novel, unrelated TRIT1 cases with abnormalities in oxidative phosphorylation complexes I and IV in fibroblasts. Taken together the features of all 15 patients, TRIT1 defect could be identified as a potentially recognizable syndrome including myoclonic epilepsy, speech delay, strabismus, progressive spasticity, and variable microcephaly, with normal lactate levels. Half of the patients had oxidative phosphorylation complex measurements and had multiple complex abnormalities.
Abstract PO032: Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-TRAIL-R Mediates Cholangiocarcinoma Tumor Immune Evasion by Enhancing Myeloid-Derived Suppressive Cell Population
Loeuillard, Emilien , Yang, Jingchun, Hai-dong, Dong, Yang, Jingchun, Haidong, Dong, Gores, Gregory J. , Ilyas, Sumera I.

Mayo Clinic

Clinical Cancer Research | September 1, 2022 | Volume: 28 | Issue: 17_Supplement | Pages: PO032-PO032

10.1158/1557-3265.liverca22-po032 Get It

Abstract Background and Aims: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a member of TNF superfamily, is predominantly expressed on immune cells. Engagement of TRAIL with its cognate receptor, TRAIL-R (TR), leads to cancer cells apoptosis. Although the anti-tumor role of TRAIL-TR has been extensively studied, TRAIL agonists have had very limited anti-cancer activity in human clinical trials. TRAIL signaling can facilitate the myeloid response. However, this potential immunosuppressive function of TRAIL has not been examined extensively in cancer biology. Cholangiocarcinoma (CCA), a highly lethal biliary tract cancer, has a dense immunosuppressive microenvironment. Accordingly, CCA provides a model to examine the potential immune regulatory function of TRAIL in cancer biology. Methods: Using syngeneic, orthotopic murine models of CCA, (PMID: 29464042), murine CCA cells (SB cells) that express both Trail and Trail receptor (Tr) were implanted into livers of WT Tr− / − and LyzcreTrf/f mice, the latter have a specific deletion of TRAIL-R on myeloid cells. Hence, in this model the host immune cells express Trail but not the receptor; therefore, they would be capable of inducing TRAIL-mediated apoptosis in CCA cells but would be resistant to TRAIL-mediated immunosuppression. After 4 weeks of tumor growth, mice were sacrificed, and tumors were characterized using flow cytometry. Results: We observed that Tr− / − mice had a significant reduction in tumor burden compared to WT mice. Myeloid-derived suppressor cells (MDSCs) were significantly decreased in Tr− / − tumors compared to WT tumors. Implantation of SB cells into LyzcreTrf/f mice resulted in a marked reduction in tumor burden and attenuation of MDSC infiltration compared to Lyzcre mice. In vitro functional studies employing MDSCs from mice deficient in Tr (MDSC-Tr −/−) were carried out. Compared to WT MDSCs, coculture of MDSC-Tr− /- with SB cells resulted in a significant reduction in the proliferation and immunosuppressive function of MDSCs. Moreover, following cocultured with SB cells, immunofluorescence analysis demonstrated that MDSC-Tr− / − had a reduction in the nuclear translocation of the NFkB subunit P65 compared to WT MDSCs. These data suggest that TRAIL-TR augments MDSC proliferation via NFkB. In conclusion, we have demonstrated that Tr− / − mice have a significant reduction in CCA tumor burden and MDSC infiltration. These results indicate that TRAIL-TR facilitates tumor immune escape and progression by fostering MDSC immunosuppressive function and infiltration, in an NFkB-dependent manner. Direct targeting of TRAIL on CCA cells is a potential anti-tumor strategy. Citation Format: Emilien Loeuillard, Jingchun Yang, Dong Haidong, Gregory Gores, Sumera Ilyas. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-TRAIL-R Mediates Cholangiocarcinoma Tumor Immune Evasion by Enhancing Myeloid-Derived Suppressive Cell Population [abstract]. In: Proceedings of the AACR Special Conference: Advances in the Pathogenesis and Molecular Therapies of Liver Cancer; 2022 May 5-8; Boston, MA. Philadelphia (PA): AACR; Clin Cancer Res 2022;28(17_Suppl):Abstract nr PO032.
Abstract IA21: Molecular Pathogenesis and Cells of Origin of Intrahepatic Cholangiocarcinoma
Ilyas, Sumera I.

Mayo Clinic

Clinical Cancer Research | September 1, 2022 | Volume: 28 | Issue: 17_Supplement | Pages: IA21-IA21

10.1158/1557-3265.liverca22-ia21 Get It

Abstract Intrahepatic cholangiocarcinoma (iCCA) originates in the intrahepatic biliary tree above the second order bile ducts. There are two primary histological subtypes of iCCA: small bile duct iCCAs which arise at the level of the smaller intrahepatic bile ducts, and large bile duct iCCAs which arise in the large intrahepatic bile ducts. Hepatic stem or progenitor cells and cuboidal cholangiocytes are the cells of origin of small bile duct iCCA, whereas large bile duct iCCAs arise from columnar mucous cholangiocytes or peribiliary glands. The molecular pathogenesis of iCCA is distinct from the other anatomic subtypes of CCA. Potentially actionable genomic aberrations that occur in iCCA include fibroblast growth factor receptor 2 (FGFR2) gene fusions, isocitrate dehydrogenase (IDH) 1 and 2 mutations, BRAF mutations, and neutrotrophic tyrosine receptor kinase (NTRK) gene fusions. Epigenetic aberrations that occur in iCCA include inactivating mutations of chromatin remodeling genes such as BAP1 and ARIDIA. Additionally, IDH 1/2 mutations lead to the production of oncometabolites with consequent widespread epigenetic changes. IDH inhibitors and FGFR inhibitors have now received FDA approval for IDH mutated and FGFR altered CCA, respectively. Immune checkpoint inhibition has received tissue agnostic FDA approval for mismatch repair deficient/MSI high CCAs. Other targeted therapies such as PARP inhibitors and CDK4/6 inhibitors are under active investigation. Citation Format: Sumera I Ilyas. Molecular Pathogenesis and Cells of Origin of Intrahepatic Cholangiocarcinoma [abstract]. In: Proceedings of the AACR Special Conference: Advances in the Pathogenesis and Molecular Therapies of Liver Cancer; 2022 May 5-8; Boston, MA. Philadelphia (PA): AACR; Clin Cancer Res 2022;28(17_Suppl):Abstract nr IA21.
Abstract IA26: FGFR2 fusion inhibitors: Clinical benefit and mechanisms of resistance
Borad, Mitesh J.

Mayo Clinic

Clinical Cancer Research | September 1, 2022 | Volume: 28 | Issue: 17_Supplement | Pages: IA26-IA26

10.1158/1557-3265.liverca22-ia26 Get It

Abstract The fibroblast growth factor pathway (FGFR) has been implicated in a subset of hepatobiliary cancers. Predominant amongst these are fusions/rearrangements for FGFR2 in ~10-15% of intrahepatic cholangiocarcinomas. In this talk we will review: (1) the FGFR pathway and its role in normal physiology, (2) sequencing studies in cholangiocarcinoma with emphasis on discovery of FGFR2 fusions, (3) clinical data for FDA approved FGFR small molecule tyrosine kinase inhibitors, (4) clinical data for second and third generation FGFR inhibitors, (5) determinants of response to therapy for FGFR inhibitors, (6) mechanisms of resistance to FGFR inhibitors and (7) on and off target toxicities for first generation FGFR inhibitors. Citation Format: Mitesh Borad. FGFR2 fusion inhibitors: Clinical benefit and mechanisms of resistance [abstract]. In: Proceedings of the AACR Special Conference: Advances in the Pathogenesis and Molecular Therapies of Liver Cancer; 2022 May 5-8; Boston, MA. Philadelphia (PA): AACR; Clin Cancer Res 2022;28(17_Suppl):Abstract nr IA26.
Most Cited Articles in Body Contouring: A Bibliometric Analysis of the Past 45 Years
Antezana, Luis A. , Kreutz‐Rodrigues, Lucas , Shapiro, Daniel , Chen, Austin, Sharaf, Basel , Martinez‐Jorge, Jorys, Bakri, Karim , Antezana, Luis , Sharaf, Basel A

Mayo Clinic

Plastic Surgery | September 1, 2022 | Volume: 32 | Issue: 2 | Pages: 265-275

10.1177/22925503221120574 | PMID 38681248 Get It

Introduction: The purpose of this study is to produce a bibliometric review of the 30 most cited articles related to 6 major domains of body contouring—abdominoplasty, thighplasty, brachioplasty, gluteoplasty, body lift, and liposuction—for resident and fellow education. Methods: The authors utilized the Web of Science Citation Index to identify the 30 most cited articles related to surgery for body contouring published from 1975 to 2020. Articles were classified according to their level of evidence, type of study, and country of publication. Results: A total of 336 articles were reviewed to compile our list. The mean number of citations across the articles was 114.7 ± SD 86.1. The highest prevalence of the papers was published between 2000 and 2009 (n = 15, 50%). The country with the highest number of contributions was the United States (n = 22, 73%). Plastic and Reconstructive Surgery served as the main journal of publication for these papers (n = 22, 73.3%). The majority of articles were designated for clinical-type studies (n = 26, 86.7%). No basic science or prevalence study design papers were listed. In terms of level of evidence (LoE), most papers were assigned IV (n = 11, 36.7%) and III (n = 7, 23.3%). Conclusions: Our study reveals that the most cited papers in body contouring are of LoE III and IV. Although the LoE of plastic surgery research, in general, has improved, in the past decade, a call for higher quality papers remains. Overall, this analysis provides an easy, electronic starting point for residents and fellows interested in understanding the field's evolution.